Evidence map›Paper›PMID 38840394›Full record

ArticleCurrent topics in medicinal chemistry2024

Gallocin-derived Engineered Peptides Targeting EGFR and VEGFR in Colorectal Cancer: A Bioinformatic Approach.

Batoul Kavyani, Fereshteh Saffari, Ali Afgar, Sajjad Kavyani, Masoud Rezaie, Fatemeh Sharifi, Roya Ahmadrajabi

Abstract read
PubMed Publisher
In one paragraph

Article in Current topics in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Batoul KavyaniDepartment of Medical Microbiology (Bacteriology and Virology), Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0003-3723-7813
Fereshteh SaffariDepartment of Medical Microbiology (Bacteriology and Virology), Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0001-7281-7077
Ali AfgarResearch Center for Hydatid Disease in Iran, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0002-4487-8523
Sajjad KavyaniDepartment of Chemical and Materials Engineering, University of Alberta, Edmonton, Alberta, T6G 1H9, Canada.ORCID 0000-0002-9716-3839
Masoud RezaieStudent Research Committee, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Fatemeh SharifiResearch Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
Roya AhmadrajabiDepartment of Medical Microbiology (Bacteriology and Virology), Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) treatment using time-saving and cost-effective targeted therapies with high selectivity and low toxicity drugs, is a great challenge. In primary investigations on Gallocin, as the most proposed factor in CRC pathogenesis caused by

objectiveThe aim of this study was to determine the ability of Gallocin-based anticancer peptides (ACPs) against epidermal growth factor receptor (EGFR) and vascular epidermal growth factor receptor (VEGFR) and the evaluation of their pharmacokinetic properties using bioinformatic approaches.

methodsSupport vector machine algorithm web-based tools were used for predicting ACPs. The physicochemical characteristics and the potential of anti-cancer activity of Gallocin-derived ACPs were determined by

resultsFour amino acid sequences with anti-cancer potential were selected. Through molecular docking, Pep2, and Pep3 gained the best scores, more binding affinity, and strong attachments by the formation of reasonable H-bonds with both EGFR and VEGFR. Molecular simulation confirmed the stability of Pep3- EGFR. According to pharmacokinetic analysis, the ACPs were safe and truthful.

conclusionDesigned peptides can be nominated as drugs for CRC treatment. However, different

Indexed as

Antineoplastic AgentsColorectal NeoplasmsComputational BiologyErbB ReceptorsPeptidesBacteriocinsCell ProliferationDrug Screening Assays, AntitumorHumansMolecular Docking SimulationReceptors, Vascular Endothelial Growth FactorAntineoplastic AgentsBacteriocinsEGFR protein, humanErbB ReceptorsPeptidesReceptors, Vascular Endothelial Growth FactorColorectal cancerDrug designEGFRGallocinIn silico.VEGFR

Identifiers

PMID38840394

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.